Vicore Pharma develops novel pharmaceutical drugs with capabilities in stimulating the AT2receptor and thereby address large unmet clinical needs in cardiovascular disease and other conditions where healing can take place with the help of AT2stimulation. Based on its proprietary and documented substances and under the expert leadership of Vita Nova Ventures and strategic R&D partners the company shall develop and market its patents and know-how.
The highly prestigious scientific journal Circulation has published a manuscript submitted by Drs. Kaschina, Steckelings, Unger and co-workers from the Center for Cardiovascular Research, Charité – Universitätsmedizin, Berlin (Circulation 2008 Nov 24, Epub ahead of print, DOI: 10.1161/CIRCULATIONAHA.108.784868). The manuscript entitled “Angiotensin II Type 2 Receptor Stimulation – A Novel Option of Therapeutic Interference with the Renin-Angiotensin System in Myocardial Infarction" (see link to PubMed citation below)summarizes the results achieved by treating rats after myocardial infarction with Vicore Pharma’s proprietary “compound 21”. Cardiac function of “compound 21” treated rats was significantly improved and infarct scar reduced when compared to vehicle treated animals, which was a result of attenuated inflammation and apoptosis within the periphery of the infarct area. The study results are interpreted as a strong proof-of-principle for the company’s drug candidate.
Further manuscripts are due for submission shortly and Vicore Pharma foresees a further increase in the scientific and consequent commercial interest for the company’s proprietary drugs.